Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

Agilent Technologies Inc.. (10/29/18). "Press Release: Agilent Sends Letter to the SEC Regarding Material Misstatements in Twist Bioscience's S-1 Registration Statement". Santa Clara, CA.

Region Region United States (USA)
Organisation Organisation Twist Bioscience Corporation (Nasdaq: TWST)
Product Product oligo synthesis
Persons Person LeProust, Emily M. (Twist Bioscience 2013– CEO + Co-Founder before Agilent Director Genomics Application Development)
  Person 2 Notaney, Stefanie (Agilent 201801)
     


Agilent Technologies Inc. (NYSE: A) today announced that it sent a letter to the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding misstatements in the S-1 Registration Statement filed by Twist Bioscience Corp.

The letter informs the SEC that "Twist's S-1 Fails to Disclose that Twist CEO Emily Leproust Formed Twist While an Employee at Agilent, and Became its CEO 17 Months Prior to Resigning from Agilent." The letter also informs the SEC that "Twist's S-1 Fails to Disclose the Material Fact that its CEO Emily Leproust and Other Twist Employees Took and Retained Hundreds of Confidential Documents Containing Agilent's Trade Secrets and Proprietary Information."

Ms. Leproust admitted under oath that she secretly became Twist's CEO 17 months prior to leaving Agilent. Agilent's Proposed Second Amended Complaint (accessible here) describes in detail Agilent's allegations that during that time, Ms. Leproust raised money to start a competitive company that would misappropriate Agilent's innovations of the past 20 years, poach Agilent's employees, and compete in the same markets with the same basic technology—all while owing a statutory duty of loyalty to Agilent.

The full text of Agilent's letter to the SEC is available here. [ ¨
https://www.agilent.com/about/newsroom/resources/2018/october-29-2018-letter-to-sec.pdf ]


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. Information about Agilent is available at www.agilent.com.


Media Contact

Stefanie Notaney
+1 408 345 8955
stefanie.notaney@agilent.com

   
Record changed: 2018-12-21

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top